Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

Daigo Yamamoto,Nobuaki Sato,Yoshiaki Rai,Yutaka Yamamoto,Mitsue Saito,Hiroji Iwata,Norikazu Masuda,Shoji Oura,Junichiro Watanabe,Satoshi Hattori,Yoshimasa Matsuura,Katsumasa Kuroi

Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

2017

Daigo Yamamoto
Nobuaki Sato
Yoshiaki Rai
Yutaka Yamamoto
Mitsue Saito
Hiroji Iwata
Norikazu Masuda
Shoji Oura
Junichiro Watanabe
Satoshi Hattori
Yoshimasa Matsuura
Katsumasa Kuroi

Purpose The randomized phase III JO21095 trial compared the efficacy and safety of low-dose capecitabine plus docetaxel combination therapy (XT) versus single-agent administration of docetaxel in anthracycline-pretreated HER2-negative metastatic breast cancer.

Keywords:

Capecitabine
HER2 negative
Oncology
Combination therapy
Anthracycline
Metastatic breast cancer
Internal medicine
Docetaxel
Medicine
low dose
single agent

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations